Myriad Genetics Names Raj Jampa as New Chief Technology Officer
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) appointed Raj Jampa as chief technology officer effective June 1, 2026. He will lead technology strategy and execution, including expanding AI use to improve efficiency, digital foundations, and customer experience, supporting Myriad’s molecular diagnostics and precision medicine growth strategy.
Positive
- None.
Negative
- None.
News Market Reaction – MYGN
In the Jun 2 session, MYGN gained 0.70%, reflecting a mild positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | ASCO MRD data | Positive | +2.1% | New Precise MRD assay data and ASCO presence supported modest share gains. |
| May 26 | AI product launch | Positive | +2.1% | Launch of Prolaris + AI prostate cancer test drove a positive price reaction. |
| May 15 | Patient story campaign | Neutral | -1.1% | Hereditary cancer awareness partnership coincided with a small share move. |
| May 07 | Investor conferences | Positive | +4.9% | Upcoming healthcare conferences and investor meetings were met with share gains. |
| May 05 | Q1 2026 earnings | Negative | -18.3% | Modest revenue growth but larger net loss triggered a sharp selloff. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent MYGN news events often saw price moves consistent with the news tone, including a sharp decline on earnings and moderate gains on product and conference updates.
Over the past month, Myriad reported Q1 2026 results on May 5 with a -18.29% move, then participated in investor conferences on May 7 with a 4.89% gain. Subsequent news highlighted patient stories, an AI-enabled Prolaris launch, and ASCO MRD data, each linked to modest price reactions around ±2%. Today’s CTO appointment fits into this broader narrative of technology, AI, and oncology-focused execution.
Key Terms
molecular diagnostic testing medical
precision medicine medical
chief technology officer technical
AI technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the appointment of Raj Jampa as chief technology officer (CTO), effective June 1, 2026.
“Raj is a proven technology leader with the vision and execution experience to help scale our business and accelerate technology innovation across the enterprise,” said Sam Raha, Chief Executive Officer, Myriad Genetics. “His leadership will be instrumental in strengthening our digital technology foundation, enhancing customer experience and supporting the next phase of Myriad’s growth and value creation.”
As CTO, Jampa will be responsible for strategy and execution of Myriad’s technology organization, including further leveraging AI to drive increased efficiency and effectivity.
“I’m honored to join Myriad at such an important time in its growth,” said Jampa. “I look forward to partnering across the enterprise to modernize our technology foundation, scale data and AI capabilities, and deliver solutions that create meaningful impact for patients, providers and the business.”
Before joining Myriad Genetics, Jampa held senior technology leadership roles at Agilent Technologies, Exact Sciences and Genomic Health, where he led large-scale transformation initiatives across enterprise platforms, digital capabilities and operating models. His experience modernizing technology infrastructure and scaling AI-enabled capabilities positions him well to help advance Myriad’s growth strategy and mission.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit myriad.com.
Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that Jampa’s leadership will be instrumental in strengthening Myriad’s digital technology foundation, enhancing customer experience and supporting the next phase of Myriad’s growth and value creation . These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
